EQRx to Hold First Quarter 2023 Financial Results Conference Call on Monday, May 8, 2023
EQRx, Inc. (Nasdaq: EQRX) announced that it will hold a conference call and webcast on May 8, 2023, at 4:30 p.m. ET to discuss its first quarter 2023 financial results and provide a business update. EQRx focuses on developing innovative medicines for prevalent diseases such as cancer and immune-inflammatory conditions. The company aims to enhance access to its products through cutting-edge science, technology, and strategic partnerships. Investors can join the call via a registration link to receive dial-in information, and a replay will be available on the company’s website approximately two hours post-event. This event will be critical for stakeholders looking to gauge EQRx's financial health and strategic direction.
- Announcement of first quarter 2023 financial results will provide clarity on financial health.
- Focus on innovative medicines for prevalent diseases may attract investor interest.
- None.
CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions, today announced it will host a conference call and webcast on Monday, May 8, 2023, at 4:30 p.m. ET to report its first quarter 2023 financial results and provide a business update.
A live webcast of the call will be available on the “Investor Relations” page of the Company’s website at https://investors.eqrx.com/news-events/events-presentations. To access the call by phone, participants should visit this link (registration link) to receive dial-in details. Participants are requested to register at least 15 minutes before the start of the call. The webcast will be made available for replay on the Company’s website beginning approximately two hours after the event.
About EQRx
EQRx is a new type of pharmaceutical company committed to developing and expanding access to innovative medicines for some of the most prevalent disease areas, including cancer and immune-inflammatory conditions. Launched in January 2020, EQRx is leveraging cutting-edge science, technology and strategic partnerships with stakeholders from across the healthcare system toward the goal of increasing access for patients around the world. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRx_US, LinkedIn.
EQRx™ and Remaking Medicine™ are trademarks of EQRx.
EQRx Contacts:
Media:
Dan Budwick
1AB
dan@1abmedia.com
Investors:
investors@eqrx.com
FAQ
What date will EQRx report its first quarter 2023 financial results?
How can I access the EQRx conference call?
What is the focus of EQRx's business?
